Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALARICE: Avelumab + Axitinib in Cervical Cancer
NCT03826589Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Jun 2019
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab and axitinib in Cervical Cancer (CC), sponsored by The University of Hong Kong. Primary endpoint: Objective Response Rate at 2 years. Started Jun 2019; status: completed.
02
Drugs
avelumabaxitinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03826589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826589.